24th Mar 2020 06:55
(Alliance News) - Medical devices manufacturer Creo Medical Group PLC on Monday said that it has received clearance from the US Food & Drug Administration for its HS1 haemostasis device.
HS1 is a single use device for endoscopic use with injection therapy. This enables it to be used to stop bleeding during treatments for peptic ulcers, dieulafoy lesions, Mallory-Weiss tears, bleeding polyp stalks, arteriovenous malformations and angiomata, Creo said.
The device will be used with Creo's Croma Advanced Energy Platform and alongside the already FDA-cleared Speedboat device.
Cero additionally said that it is exploring opportunities to make available its medical technology team and clinical experts to assist the UK's National Health Service in its management of the Covid-19 outbreak.
Craig Gulliford, chief executive officer of Creo, said: "While COVID-19 presents challenges and uncertainties for us as much as any business, we are well funded and will be ready as and when the related restrictions are eased. In the meantime, we are ready to support sector initiatives to accelerate the supply of medical equipment into the NHS".
Shares in Cero on Monday closed at 111.80 pence each on Monday, down 0.6%,
By Tapan Panchal; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Creo Medical